Article
Paris - Increased understanding of the basic molecular mechanisms involved in angiogenesis has suggested new targets for treating a number of dermatological and other diseases, and many compounds affecting angiogenesis are in clinical trials. However, questions remain to be answered about potential strategies for optimizing the efficacy of pro- and anti-angiogenic interventions and the safety of these novel treatments, Peter Carmeliet, Ph.D., said at the World Congress of Dermatology.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.